


Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis

Supplementary materials


((randomized controlled trial[Publication Type] OR randomized[Title/Abstract] OR placebo[Title/Abstract]) AND (((((((((((((((((((((((Immuno[MeSH Terms] OR (PD-1[Title/Abstract])) OR (PD-L1[Title/Abstract])) OR (CTLA-4[Title/Abstract])) OR (Pembrolizumab[Title/Abstract])) OR (Keytruda[Title/Abstract])) OR (lambrolizumab[Title/Abstract])) OR (MK-3475[Title/Abstract])) OR (Nivolumab[Title/Abstract])) OR (Atezolizumab[Title/Abstract])) OR (Tecentriq[Title/Abstract])) OR (MPDL3280A[Title/Abstract])) OR (Avelumab[Title/Abstract])) OR (Bavencio[Title/Abstract])) OR (Durvalumab[Title/Abstract])) OR (Imfinzi[Title/Abstract])) OR (Camrelizumab[Title/Abstract])) OR (Tislelizumab[Title/Abstract])) OR (Sintilimab[Title/Abstract])) OR (ipilimumab[Title/Abstract])) OR (tremelimumab[Title/Abstract])) OR (ticilimumab[Title/Abstract])) OR (((((((((((((((((((((((Angiogenesis Inhibitors[MeSH Terms] OR (Inhibitor*,Angiogen*[Title/Abstract])) OR (Antagonist* Angiogen*[Title/Abstract])) OR (Angiostatic Agent*[Title/Abstract])) OR (Anti? Angiogen* Agent*[Title/Abstract])) OR (Anti? Angiogen* Drug*[Title/Abstract])) OR (Inhibitor*, Neovascularization[Title/Abstract])) OR (VEGFR[Title/Abstract])) OR (multitargeted antiangiogenesis tyrosine kinase inhibitors[Title/Abstract])) OR (*mab[Title/Abstract])) OR (*nib[Title/Abstract])) OR (BIBF 1120[Title/Abstract])) OR (votrient[Title/Abstract])) OR (Everolimus[Title/Abstract])) OR (Aflibercept[Title/Abstract])) OR (bevacizumab[Title/Abstract])) OR (ramucirumab[Title/Abstract])) OR (nintedanib[Title/Abstract])) OR (anlotinib[Title/Abstract])) OR (apatinib[Title/Abstract])) OR (Sorafenib[Title/Abstract])) OR (Vandetanib[Title/Abstract])) OR (Sunitinib[Title/Abstract])) OR (Pazopanib[Title/Abstract])) OR (Lenvatinib[Title/Abstract])) OR (Cediranib[Title/Abstract])) OR (Motesanib[Title/Abstract])) OR (Axitinib[Title/Abstract])))) AND (((Carcinoma, Non-Small-Cell Lung[MeSH Terms] OR (Lung Carcinoma*, Non-Small-Cell[Title/Abstract])) OR (Non?Small ?Cell Lung Cancer[Title/Abstract])) OR (NSCLC[Title/Abstract]))

Table S1. Literature search strategy on pubmed.






	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
BEYOND	+	+	+	+	+	+	+
BR29	+	+	+	+	+	+	+
Camel	+	+	-	+	+	+	+
Camel-sq	+	+	+	+	+	+	+
CheckMate227	+	+	-	+	+	+	+
ECOG-4599	+	?	?	?	+	+	+
IMpower130	+	+	-	+	+	+	+
IMpower131	+	?	?	?	+	+	+
IMpower132	+	+	-	+	+	+	+
IMpower150	+	-	-	?	+	+	+
TASUKI 52	+	+	+	+	+	+	+
KEYNOTE189	+	+	+	+	+	+	+
KEYNOTE407	+	+	+	+	+	+	+
MONET1	+	+	+	+	+	+	+
ORIENT-11	+	+	+	+	+	+	+

Figure S1 Assessment of risk of bias






A: Forest plots of pairwise comparisons with heterogeneity estimates for OS






B: Forest plots of pairwise comparisons with heterogeneity estimates for PFS.






C: Forest plots of pairwise comparisons with heterogeneity estimates for safety($\geq 3AE$)


Figure S2: Forest plots of pairwise comparisons with heterogeneity.



A: Node-splitting analysis of inconsistency for OS




B: Node-splitting analysis of inconsistency for PFS




C: Node-splitting analysis of inconsistency for safety(≥ 3 AE)


Figure S3: Node-splitting analysis of inconsistency.



A: Forest plot for OS




B: Forest plot for PFS




C: Forest plot for $\geq 3AE$


Figure S4: Forest plots




A: Trace and density plots for OS




B: Brooks-Gelman-Rubin diagnosis plot for OS




C:Trace and density plots for PFS



D: Brooks-Gelman-Rubin diagnosis plot for PFS



E: Trace and density plots for grade ≥ 3 adverse events



F: Brooks-Gelman-Rubin diagnosis plot for grade ≥ 3 adverse events

Figure S5: Trace and density plots and the Brooks Gelman-Rubin diagnostic for OS (A and B), PFS (C and D) and grade ≥ 3 adverse events (E and F).